Related Experiment Video

Updated: Jun 29, 2026

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor
09:33

Genetic Profiling and Genome-Scale Dropout Screening to Identify Therapeutic Targets in Mouse Models of Malignant Peripheral Nerve Sheath Tumor

Published on: August 25, 2023

Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma

C Perfumo1, S Parodi, K Mazzocco

  • 1Molecular Mutagenesis and DNA Repair Unit, National Institute for Cancer Research, Genova, Italy. chiara.perfumo@istge.it

European Journal of Cancer (Oxford, England : 1990)
|October 7, 2008
PubMed

Insights

The MDM2 SNP309 genetic variation impacts neuroblastoma (NB) patient outcomes. Patients with the GG genotype show poorer survival rates, suggesting MDM2 SNP309 as a potential independent prognostic factor for stage 4 NB.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Neuroblastoma (NB) progression can involve the p53 checkpoint's circumvention.
  • MDM2, a key negative regulator of p53, may be upregulated in NB.
  • The MDM2 SNP309 polymorphism is linked to increased MDM2 expression and p53 pathway attenuation.

Purpose of the Study:

  • To evaluate the association between MDM2 SNP309 genotype and clinical outcomes in stage 4 neuroblastoma.
  • To determine if MDM2 SNP309 is an independent prognostic factor in this patient cohort.

Main Methods:

  • Genotyping analysis of the MDM2 SNP309 polymorphism in 142 children with stage 4 NB.
  • Statistical evaluation of genotype association with overall survival, event-free survival, and survival after relapse.
  • Correlation analysis with MYCN status.

Main Results:

  • Patients with the MDM2 SNP309 GG genotype exhibited significantly worse overall survival and post-relapse survival compared to TT homozygotes.
  • Heterozygous individuals showed intermediate survival outcomes.
  • No significant association was found between MDM2 SNP309 and event-free survival.
  • MDM2 SNP309 status was independent of MYCN status.

Conclusions:

  • MDM2 SNP309 genotype is associated with survival in stage 4 neuroblastoma patients.
  • This genetic marker may serve as a novel, independent prognostic factor for stage 4 NB, beyond MYCN status.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...